First AD

Second AD

Breast cancer specialists outline their institutions’ practices regarding the choice between subcutaneous and intravenous antibody-drug conjugates.

Clinical Impact of Subcutaneous Antibody-Drug Conjugates in HER2+ Breast Cancer

Video content above is prompted by the following question(s):

What is your institution’s approach to intravenous PH vs. subcutaneous PH in the neoadjuvant setting?

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice

Peer Exchange

Baylor Scott & White Charles A. Sammons Cancer Center 

Cancer Centers

Partner

UCLA Health Jonsson Comprehensive Cancer Center

Yale Cancer Center

VCU Massey Cancer Center

Breast cancer specialists outline their institutions’ practices regarding the choice between subcutaneous and intravenous antibody-drug conjugates in patients with HER2+ breast cancer.